A detailed history of Excalibur Management Corp transactions in Organon & Co. stock. As of the latest transaction made, Excalibur Management Corp holds 23,383 shares of OGN stock, worth $344,431. This represents 0.17% of its overall portfolio holdings.

Number of Shares
23,383
Previous 23,981 2.49%
Holding current value
$344,431
Previous $496,000 9.88%
% of portfolio
0.17%
Previous 0.2%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$18.65 - $23.03 $11,152 - $13,771
-598 Reduced 2.49%
23,383 $447,000
Q2 2024

Aug 09, 2024

SELL
$17.45 - $21.96 $5,235 - $6,588
-300 Reduced 1.24%
23,981 $496,000
Q1 2024

May 13, 2024

SELL
$13.78 - $18.8 $12,319 - $16,807
-894 Reduced 3.55%
24,281 $456,000
Q4 2023

Feb 12, 2024

SELL
$10.95 - $17.32 $22,502 - $35,592
-2,055 Reduced 7.55%
25,175 $363,000
Q3 2023

Nov 09, 2023

SELL
$16.59 - $23.77 $962 - $1,378
-58 Reduced 0.21%
27,230 $472,000
Q2 2023

Aug 08, 2023

SELL
$19.27 - $24.63 $6,089 - $7,783
-316 Reduced 1.14%
27,288 $567,000
Q1 2023

May 05, 2023

SELL
$21.42 - $32.08 $10,945 - $16,392
-511 Reduced 1.82%
27,604 $649,000
Q4 2022

Feb 10, 2023

SELL
$23.31 - $28.61 $22,657 - $27,808
-972 Reduced 3.34%
28,115 $785,000
Q3 2022

Nov 04, 2022

SELL
$23.4 - $34.25 $24,733 - $36,202
-1,057 Reduced 3.51%
29,087 $681,000
Q2 2022

Jul 25, 2022

SELL
$31.66 - $38.9 $86,241 - $105,963
-2,724 Reduced 8.29%
30,144 $1.02 Million
Q1 2022

May 03, 2022

SELL
$30.45 - $39.36 $109,650 - $141,735
-3,601 Reduced 9.87%
32,868 $1.15 Million
Q4 2021

Feb 10, 2022

BUY
$28.67 - $37.13 $25,946 - $33,602
905 Added 2.54%
36,469 $1.11 Million
Q3 2021

Oct 28, 2021

BUY
$28.63 - $35.64 $1.02 Million - $1.27 Million
35,564 New
35,564 $1.17 Million

Others Institutions Holding OGN

About Organon & Co.


  • Ticker OGN
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 254,330,000
  • Market Cap $3.75B
  • Description
  • Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio...
More about OGN
Track This Portfolio

Track Excalibur Management Corp Portfolio

Follow Excalibur Management Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Excalibur Management Corp, based on Form 13F filings with the SEC.

News

Stay updated on Excalibur Management Corp with notifications on news.